MSInsight
MSInsight is a startup focused on advancing precision cancer treatment by developing innovative biomarker detection solutions. Founded in 2022 by experts from Paris hospitals, Inserm, and Sorbonne University, the company leverages 20 years of research to address the critical need for accurate diagnosis of microsatellite instability (MSI), a key cancer biomarker. Their flagship product, MSIcare, utilizes next-generation sequencing (NGS) and advanced bioinformatics algorithms with AI to detect MSI in solid tumors and liquid biopsies. MSIcare provides actionable insights for personalized treatment plans, aiming to improve patient outcomes. MSInsight offers data analysis services to support healthcare providers in personalized treatment planning.
MSInsight
MSInsight is a startup focused on advancing precision cancer treatment by developing innovative biomarker detection solutions. Founded in 2022 by experts from Paris hospitals, Inserm, and Sorbonne University, the company leverages 20 years of research to address the critical need for accurate diagnosis of microsatellite instability (MSI), a key cancer biomarker. Their flagship product, MSIcare, utilizes next-generation sequencing (NGS) and advanced bioinformatics algorithms with AI to detect MSI in solid tumors and liquid biopsies. MSIcare provides actionable insights for personalized treatment plans, aiming to improve patient outcomes. MSInsight offers data analysis services to support healthcare providers in personalized treatment planning.